(Q40437197)

20 September 2017

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity (English)

1 reference

20 September 2017

0 references

8

1 reference

20 September 2017

Karen Kelly

5

0 references

David R Gandara

1

object named as

David R Gandara

1 reference

20 September 2017

Tianhong Li

2

1 reference

20 September 2017

Primo N Lara

3

1 reference

20 September 2017

Philip C Mack

4

1 reference

20 September 2017

Suzanne Miyamoto

6

1 reference

20 September 2017

Neal Goodwin

7

1 reference

20 September 2017

Mary W Redman

9

1 reference

20 September 2017

language of work or name

English

0 references

publication date

6 June 2012

1 reference

20 September 2017

1 reference

20 September 2017

13

1 reference

20 September 2017

5

1 reference

20 September 2017

321-325

1 reference

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

20 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Personalized oncology through integrative high-throughput sequencing: a pilot study

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Evolutionary dynamics of intratumor heterogeneity.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Clinical trial designs for predictive marker validation in cancer treatment trials

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Targeted therapy: wave of the future.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Randomized phase III clinical trial designs for targeted agents

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049356

Implications of personalized medicine--perspective from a cancer center

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22677432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evaluating the efficiency of targeted designs for randomized clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22677432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.CLLC.2012.05.004

1 reference

20 September 2017

1 reference

20 September 2017

1 reference